News

Drug candidate to be assessed for managing voluntary motor disturbances in Huntington disease JERUSALEM--(BUSINESS WIRE)--Sep. 27, 2012-- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark (OMX: NEUR) to purchase all rights, assets and obligations relating to Huntexil® (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD). Under Read More »

Patients are now being enrolled in the U.S. for the Gamida Cell-Teva Joint Venture ExCell trial studying StemEx® as an alternative treatment for bone marrow transplants. Jerusalem, Israel, November 6, 2007 - Gamida Cell-Teva Joint Venture announced today that the first patient in the international, pivotal registration ExCell study has undergone a StemEx® transplant at the Ireland Cancer Center of University Hospitals Case Medical Center. StemEx® is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded c Read More »

-- Results Demonstrate Impressive Reduction of Disease Activity-- Teva Intends to Conduct Additional Pre-Clinical and Clinical Research Before Continuing to a Phase III Study with this Unique and Promising Molecule --Jerusalem, Israel & Melbourne, Australia, June 30, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: Teva) and Antisense Therapeutics Ltd. (ASX: ANP) announced today that ATL/TV1102, a novel, anti-sense drug, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). A randomized, double-blind, placebo-controlled Phase IIa study me Read More »

Jerusalem, Israel, October 20, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase®, an enzymatic debriding agent for burns. MediWound reported that the phase III study with Debrase® for the treatment of burns met the two primary endpoints of the study reduction in the percentage of wound surgically excised and reduction in the percentage of wound autografted with statistical significance. Based on these results Read More »

Jerusalem, Israel, Lund, Sweden, February 8, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set und Read More »

Jerusalem, Israel, Bothell, WA, and Vancouver, Canada, September 30, 2010 - Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The SYNERGY trial is the second of three Phase 3 trials to be initiated under a global collaboration and license agreement between Teva and OncoGenex to develop and commercialize custirsen. The SYNERGY trial is a ran Read More »

-- New Data Suggests Novel Strategies for the Treatment of Prostate Cancer --Jerusalem, Israel, April 6, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that new preclinical data of their investigational compound custirsen (OGX-011/TV-1011) in castrate resistant prostate cancer (CRPC) were presented this week at the 102nd Annual Meeting of the AACR. These data provide additional evidence in support of the clinical potential of custirsen, a drug designed to block production of clusterin, that is currently being investig Read More »

- CT-011 Meets Primary Endpoint of Progression-Free Survival - Achieved Statistically Significant Results in Secondary Endpoint of Overall Survival Jerusalem, Israel, May 17, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody. CT-011 met the primary endpoint of improved progression-free survival (PFS), in a Phase II clinical trial in patients with Diffuse Large B Cell Lymphoma (DLBCL) following autologous Read More »

Pre-Clinical Data Show Potential Combinability and Enhanced Anti-Tumor Activity With Two Different Agents Jerusalem, Israel, Bothell, WA and Vancouver, British Columbia, May 19, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from three studies of their investigational compound custirsen (OGX-011/TV-1011) in castrate resistant prostate cancer (CRPC) will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.Custirsen is the only compound in dev Read More »

-- Investment Further Expands Oncology Pipeline ---- Investment Follows Positive Phase II Results in Lymphoma -- JERUSALEM, Sep 13, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today its decision to exercise its option to make an additional $19 million investment in CureTech Ltd., and to finance up to $50 million of the company's R&D program. Teva's decision follows the positive final results from a phase II trial in diffuse large B-Cell lymphoma (DLBCL) using CT-011, an investigational anti-PD-1 monoclonal antibody. The study met its primary end po Read More »